SCLC

Durvalumab Improves OS for Extensive Stage Small Cell Lung Cancer

Extensive stage small cell lung cancer (SCLC) has historically been associated with limited treatment options and a poor prognosis. In recent years, immunotherapy with PD-1 and PD-L1 targeting antibodies has emerged as an effective treatment option for these patients with progressive disease. Recently, the PD-L1 inhibitor atezolizumab was approved for use in the first-line setting […]

Read More

Treatment of Early Lung Cancer With Video-Assisted Surgery

Surgical resection is a standard of care for early lung cancer. However, the most frequent surgical approach, open surgical resection, is associated with a high degree of morbidity and risk of complications. Video-assisted thoracic surgery (VATS), sometimes called ‘keyhole surgery’, is an alternative approach to surgery for lung cancer, but it is currently underutilized, particularly […]

Read More

fda-approvals-june-2019

FDA Approves Three Agents for Cancer Indications

First Ever Treatment for Tenosynovial Giant Cell Tumor. The United States Food and Drug Administration (FDA) granted approval to pexidartinib (Turalio™, Daiichi-Sankyo) for treatment of patients with symptomatic tenosynovial giant cell tumor (TGCT) with severe morbidity or functional limitations who cannot be treated with surgery. The approval was based on the phase III ENLIVEN study, […]

Read More

Breast Cancer Risk Increased by Menopausal Hormonal Therapy

Menopausal hormonal therapy (MHT), used to alleviate the symptoms of menopause, has been associated with an increased risk of breast cancer; but findings from previous studies have been inconsistent and lack long-term follow-up. A large, new meta-analysis of published and unpublished sources evaluated 108,647 postmenopausal women, who developed breast cancer, for history of MHT use […]

Read More